Aqualung Therapeutics is a Tucson, AZ and Jupiter, FL -based biotech company that has

❖ Developed ALT-100 mAb, a novel, anti-eNAMPT, anti-inflammatory and anti-fibrotic monoclonal antibody

❖ Identified eNAMPT (extracellular nicotinamide phosphoribosyltransferase) as a key DAMP and upstream activator of  inflammatory and fibrosis cascades

❖ Developed the “eNamptor™ Platform” strategy (mAb, biomarker, genotype) for serious inflammatory, fibrotic and autoimmune disorders

❖ Published peer-reviewed work demonstrating the efficacy of the ALT-100 mAb in preclinical models of ARDS/VILI, Radiation-Induced Lung Injury/Fibrosis, Organ Fibrosis (Lung, Liver, Heart,  colon), Pulmonary Hypertension, Systemic Lupus Vasculitis,  Chorioamnionitis (associated with premature births), Prostate Cancer